{"disease":{"id":"refractory-systemic-lupus-erythematosus","name":"refractory systemic lupus erythematosus"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06530849","title":"A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":118,"lead_sponsor_name":"Gracell Biotechnologies (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT06694298","title":"A Study of SYS6020 Injection in Refractory Active Systemic Lupus Erythematosus","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT07339540","title":"the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT07523542","title":"SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT06676631","title":"NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT05474885","title":"BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"iCell Gene Therapeutics","has_results":false},{"nct_id":"NCT05930314","title":"CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":12,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT07083349","title":"NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Base Therapeutics (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT07490275","title":"Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06513429","title":"IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)","phase":"NA","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"Peking University Third Hospital","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}